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Scisplatin-fibrin, which has to be further evaluated. In a next
step, we will further evaluate the application of cisplatin-
fibrin on the whole surface of the chest cavity before start-
ing a clinical phase I study.
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Dr W. Roy Smythe (Temple, Tex). I appreciate the opportunity
to comment on this paper and I also thank the authors for sending
the manuscript ahead of time. Walt Whitman said the art of art, the
glory of expression, and the sunshine of the light of letters is sim-
plicity. The use of intrapleural chemotherapy for an intrapleural
malignancy suggests Whitman’s simplicity; however, this tech-
nique, which was originally experimentally pioneered by Valerie
Rusch and colleagues at Memorial Sloan–Kettering and David
Sugarbaker and his colleagues at Brigham, followed by more
than a decade of clinical use, pioneering clinical use by the Brig-
ham group, has been less than anticipated. In all likelihood, most
of the issues with this approach have related to the lack of persis-
tence of the drug at the site and then the associated toxicities,
which your group has mentioned. I think this study, on the other
hand, is very simple and elegant and begins to address some
of these issues. I have the following questions: First, is there any
evidence that the fibrin carrier interacts with the drug, either
augmenting or attenuating the effect of the drug? I noticed that
the snake-derived venom, batroxobin, is used in this formulation.
Batroxobin, for example, is a serine protease, which has been
shown itself in many animal models of malignancy to have an
antitumor effect.
Dr Opitz. We could not address this in the pig model because
this is not a tumor model. However, in our previous small animal
studies, we also analyzed a group treated with fibrin alone and we
observed no antitumor efficacy with fibrin alone.
Dr Smythe. Very good. The second question is, if the major
mechanism of action here is the film holding the drug in place
for a period of time, that would suggest that other drugs or even
biological agents might be applicable to this model. Have you tried
those in the past in any of your models?
DrOpitz.We have tried chemokines that were topically applied
and we have tried CpG-ODNs, but the efficacy was not higher with
these drugs if combined to fibrin in comparison to cisplatin, as it is
already very active. However, there are a lot of options to test this
in the future. Any drug can be combined with fibrin.
Dr Smythe. The last question is, one of the other issues with in-
trapleural chemotherapy, one of the reasons some groups have
used heated chemotherapy rather than just simple installation, is
depth of penetration of the drug. A group that I previously worked
with showed in 2005 that if you use a liposomal formulation of cis-
platin, you can get better depth of penetration in tumor. Have you
considered perhaps using this fibrin carrier in combination with
a lipid carrier to maybe titrate depth of penetration?
Dr Opitz. We discussed this issue during the setup of our pro-
tocol. However, in the literature, there is really a high rate ofry c January 2011
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Spulmonary embolism and deep venous thrombosis in the clinical
phase I and phase II studies, and it has been demonstrated that
hyperthermia leads to fibrin formation or disorganization of the
whole coagulation cascade. We decided for our protocol not to
use hyperthermia.
Dr Steven J. Mentzer (Boston, Mass). A poorly recognized
biological characteristic of cisplatin is that it can generate anThe Journal of Thoracic and C
Gimmunologic response by directly modifying class I peptides. It
is possible that some of the clinical response you observe may
be immunologically mediated? The potential immunologic activ-
ity of cisplatin raises concerns about the biological availability
of cisplatin after fibrin conjugation. Do you have any data that
cisplatin is biologically active?
Dr Opitz. No, we do not have any data.ardiovascular Surgery c Volume 141, Number 1 71
